Free Trial
NASDAQ:SLRN

Acelyrin Q4 2024 Earnings Report

Acelyrin logo
$2.57 -0.01 (-0.39%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.58 +0.01 (+0.19%)
As of 05/2/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acelyrin EPS Results

Actual EPS
-$0.79
Consensus EPS
-$0.86
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Acelyrin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acelyrin Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 19, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Acelyrin's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Acelyrin Earnings Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
Alumis and ACELYRIN Announce Amended Merger Agreement
See More Acelyrin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acelyrin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acelyrin and other key companies, straight to your email.

About Acelyrin

Acelyrin (NASDAQ:SLRN), a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

View Acelyrin Profile

More Earnings Resources from MarketBeat